GlobeNewswire by notified

XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study

Share

Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic Cancer

AUSTIN, Texas, June 20, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today it successfully completed the Phase I portion of its 1-BETTER study, a Phase I/II randomized, double-blind, placebo-controlled clinical study to evaluate its anti-cancer drug Natrunix in combination with chemotherapy for treating pancreatic cancer. Enrollment in the Phase II portion is commencing immediately.

Thirty leading cancer centers across the United States are involved in the Phase I/II study. Pancreatic cancer is the 4th leading cause of cancer death in the United States and the incidence has been increasing steadily since 2000. In 2022 about 50,000 people will die from pancreatic cancer in the United States. The Natrunix antibody therapy represents a groundbreaking approach to therapy—with the aim to of reducing treatment related toxicity of chemotherapy while also blocking the tumor-associated signals that spurn growth and spread of tumors.

The key is Natrunix’s ability to specifically target the body’s response to injury. Chemotherapy and tumors both elicit an injury response from the body, and this response may counteract some of the beneficial effects of therapy while at the same time cause substantial morbidity. This injury response plays a crucial role in the growth, spread and morbidity of cancer. Natrunix targets this common pathway activated by cytotoxic therapy and paraneoplastic inflammation. Used in combination with chemotherapy, Natrunix is therefore being assessed for its ability to reduce the side effects of chemotherapy treatment and mediate anti-tumor effects.

The Phase I study enrolled patients in three groups, using escalating dose levels of Natrunix. Subjects received the maximum dosing of Natrunix without a single report of “possibly, probably, or definitely related dose limiting toxicity (DLT)” associated with the investigational agent. Subjects received two 14-day cycles of Natrunix in combination with the chemotherapy drugs Onivyde, 5-fluorouracil and leucovorin. At the discretion of the treating oncologist, after completing the two 14-day cycles, patients were allowed to continue to receive Natrunix if they were deemed to be potentially benefiting from the investigational agent. All patients in the highest dose group have continued to receive Natrunix; at this time a total of 14 additional cycles of therapy have been administered to the Phase I subjects.

Dr. David Park, Medical Director, Hematology, Medical Oncology, St Jude Crosson Cancer Institute, Providence OC Cancer Institute stated, "Natrunix has shown to be well-tolerated when administered concurrently with chemotherapy. We are seeing early encouraging signs that this investigational agent may have a salutary effect in patients via its action in the inflammatory pathway(s).”

The Phase II portion of the study is commencing immediately. Key endpoints in the Phase II portion will be progression-free survival, overall survival and time-to-treatment-failure. The Phase II portion is enrolling 60 subjects that will be randomized on a 1:1 basis to receive either Natrunix in combination with ONIVYDE+LV+5-FU (Arm 1), or placebo plus the chemotherapy combination. Subjects will receive the treatment for up to 12 cycles and will be allowed to continue to receive Natrunix if they were deemed to be potentially benefiting from the investigational agent.

About Natrunix
Natrunix is a True Human™ antibody that was discovered, developed and manufactured by XBiotech. True Human™ antibodies are derived—without modification—from individuals who possess natural immunity to certain diseases. In many individuals, the body naturally produces antibodies to block pathological inflammation associated with interleukin-1, one of the most extensively studied inflammatory pathways in medicine. Other marketed biological drugs attempt to treat diseases by blocking interleukin-1, however none specifically and exclusively target interleukin-1 alpha (IL-1a). There is also no other marketed monoclonal antibody therapy derived unaltered from a natural human immune response.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech is currently advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions, and infectious diseases. Headquartered in Austin, Texas, XBiotech is also leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact

Wenyi Wei
wwei@xbiotech.com
Tel. 512-386-2900

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Cool Company Ltd. – Formation Completed1.7.2022 18:46:54 CEST | Press release

Golar LNG Limited ("Golar") announces today that it has sold to Cool Company Ltd. (“CoolCo”) the management organization responsible for the technical and commercial management of LNG carriers, and the provision of such services to third parties, as contemplated in the January 2022 Cool Company Ltd. formation update. CoolCo paid the previously agreed purchase price of $5 million in cash for the shares plus $1.5 million in working capital. As part of the transaction, approximately 600 maritime and office-based personnel became CoolCo employees. Today, Richard Tyrrell also assumed his position as CEO of CoolCo, replacing Interim CEO Karl Fredrik Staubo. FORWARD LOOKING STATEMENTS This press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended) which reflects management’s current expectations, estimates and projections about its operations. All statements, other than statements of historical facts, that address activitie

Cool Company Ltd. - Formation Completed1.7.2022 18:37:43 CEST | Press release

Cool Company Ltd. ("CoolCo" or the "Company") is pleased to announce today that it has acquired from Golar Management (Bermuda) Limited the management organization responsible for the technical and commercial management of its LNG carriers and the provision of such services to third parties, as contemplated in the January 2022 Cool Company Ltd. formation update. CoolCo paid the previously agreed purchase price of $5 million in cash for the shares plus $1.5 million in working capital. As part of the transaction, approximately 600 maritime and office-based personnel become employees of CoolCo. Today, Richard Tyrrell also assumed his position as CEO of CoolCo, replacing interim CEO Karl Fredrik Staubo. Richard Tyrrell commented: “CoolCo is delighted to formally welcome the members of the Golar LNG team that provide first class technical and commercial management services to our owned fleet of eight LNG carriers, in addition to providing such services to 20 third party vessels. The acquisi

U.S. Government Orders Additional Monkeypox Vaccines from Bavarian Nordic1.7.2022 16:00:10 CEST | Press release

Bavarian Nordic to supply an additional 2.5 million doses of JYNNEOS® vaccineDoses will be manufactured using existing bulk vaccine from previous orders from BARDADeliveries starting in the fourth quarter of 2022 with the majority to be delivered in 2023 COPENHAGEN, Denmark, July 1, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has ordered an additional 2.5 million doses of liquid-frozen JYNNEOS®, a non-replicating smallpox vaccine and the only FDA-approved vaccine against monkeypox. Deliveries under this contract will start in the fourth quarter of 2022 and continue through early 2023. This order comes a few weeks after an order from BARDA for the delivery of 500,000 doses of the vaccine in 2022 in response to the current monkeypox outbreak. With a previous order from BARD

Den amerikanske regering bestiller yderligere vacciner mod abekopper fra Bavarian Nordic1.7.2022 16:00:10 CEST | pressemeddelelse

Bavarian Nordic skal levere yderligere 2,5 mio. doser JYNNEOS® vaccineRåvaccine, produceret under tidligere kontrakter med BARDA, vil blive anvendt til færdigproduktion af doserneLeverancerne vil starte i fjerde kvartal 2022 og fortsætte ind i 2023, hvor hovedparten af doserne vil blive leveret KØBENHAVN, Danmark, 1. juli 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at Biomedical Advanced Research and Development Authority (BARDA), en del af Office of the Assistant Secretary for Preparedness and Response ved U.S. Department of Health and Human Services, har bestilt yderligere 2,5 mio. doser af den flydende-frosne udgave af JYNNEOS®, en ikke-replikerende koppevaccine, og den eneste FDA-godkendte vaccine mod abekopper. Leverancerne vil starte i fjerde kvartal 2022 og fortsætte ind i begyndelsen af 2023. Denne ordre er afgivet få uger efter en anden ordre fra BARDA på levering af 500.000 doser af vaccinen i 2022 til brug i forbindelse med det aktuelle udbrud af abekopper. Med en

Incap Corporation: INCAP GROUP’S HALF-YEAR FINANCIAL REPORT FOR JANUARY–JUNE 2022 AND WEBCAST 28 JULY 20221.7.2022 14:30:00 CEST | Press release

Incap Corporation Press release 1 July 2022 at 3:30 p.m. EEST The corrected release includes the time of the webcast. Incap Group’s half-year financial report for January–June 2022 will be published on Thursday, 28 July 2022 at approximately 09:00 a.m. Finnish time. At that time, reporting materials in Finnish and English will be available on the company's website at https://incapcorp.com/reports-and-presentations/. Webcast The company will hold a webcast on Thursday, 28 July 2022 at 2:00 p.m. EEST. The result will be presented by Otto Pukk, CEO, and Antti Pynnönen, CFO, Incap Corporation. In addition to the result, Incap's UK operations will be presented at the event, and Jamie Maughan, Director of Operations UK will participate in the event. The live webcast can be followed at https://incap.videosync.fi/2022-07-28-half-year-report. During the webcast, the public can ask questions in the chat room at the address mentioned above. The recording of the broadcast will be available on the